Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 12 | 2023 | 543 | 2.660 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 16 | 2021 | 226 | 2.120 |
Why?
|
| Antitubercular Agents | 12 | 2021 | 322 | 2.060 |
Why?
|
| Rifampin | 11 | 2019 | 197 | 1.850 |
Why?
|
| Mycobacterium tuberculosis | 5 | 2023 | 329 | 1.770 |
Why?
|
| HIV Infections | 28 | 2025 | 5097 | 1.430 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2018 | 324 | 1.030 |
Why?
|
| Antibiotics, Antitubercular | 4 | 2019 | 47 | 0.940 |
Why?
|
| Health Care Costs | 4 | 2020 | 115 | 0.910 |
Why?
|
| Adult | 31 | 2025 | 5913 | 0.850 |
Why?
|
| Anti-HIV Agents | 14 | 2025 | 1324 | 0.840 |
Why?
|
| Coinfection | 9 | 2021 | 276 | 0.820 |
Why?
|
| Male | 29 | 2023 | 6754 | 0.780 |
Why?
|
| Retrospective Studies | 17 | 2021 | 799 | 0.750 |
Why?
|
| Female | 32 | 2025 | 9103 | 0.730 |
Why?
|
| Humans | 39 | 2025 | 14537 | 0.720 |
Why?
|
| South Africa | 31 | 2023 | 7596 | 0.700 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 135 | 0.660 |
Why?
|
| Middle Aged | 19 | 2019 | 3601 | 0.610 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2018 | 132 | 0.610 |
Why?
|
| Income | 1 | 2018 | 85 | 0.600 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 59 | 0.600 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2018 | 195 | 0.550 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.550 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 12 | 0.490 |
Why?
|
| Young Adult | 12 | 2025 | 2498 | 0.420 |
Why?
|
| Treatment Outcome | 11 | 2021 | 889 | 0.410 |
Why?
|
| Adolescent | 11 | 2025 | 2985 | 0.390 |
Why?
|
| Patient Compliance | 3 | 2016 | 120 | 0.380 |
Why?
|
| Sputum | 3 | 2023 | 135 | 0.380 |
Why?
|
| Sensitivity and Specificity | 3 | 2023 | 385 | 0.360 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2018 | 656 | 0.360 |
Why?
|
| Primary Health Care | 3 | 2023 | 240 | 0.350 |
Why?
|
| Cohort Studies | 9 | 2018 | 967 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 472 | 0.310 |
Why?
|
| Drug Substitution | 2 | 2016 | 33 | 0.270 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2025 | 529 | 0.270 |
Why?
|
| Anti-Retroviral Agents | 3 | 2021 | 551 | 0.250 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2018 | 118 | 0.250 |
Why?
|
| Viral Load | 9 | 2018 | 819 | 0.230 |
Why?
|
| Pyridones | 1 | 2025 | 100 | 0.230 |
Why?
|
| Aged | 5 | 2019 | 1740 | 0.220 |
Why?
|
| Time Factors | 4 | 2017 | 507 | 0.220 |
Why?
|
| Public Sector | 3 | 2018 | 82 | 0.210 |
Why?
|
| HIV | 2 | 2023 | 380 | 0.200 |
Why?
|
| Treatment Failure | 6 | 2018 | 175 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 187 | 0.190 |
Why?
|
| Registries | 2 | 2019 | 91 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 21 | 0.190 |
Why?
|
| Abortion, Spontaneous | 1 | 2021 | 15 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 34 | 0.190 |
Why?
|
| Isoniazid | 1 | 2021 | 110 | 0.180 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 163 | 0.180 |
Why?
|
| Premature Birth | 1 | 2021 | 80 | 0.170 |
Why?
|
| Data Accuracy | 1 | 2019 | 9 | 0.170 |
Why?
|
| Politics | 1 | 2019 | 24 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 106 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2018 | 151 | 0.160 |
Why?
|
| Reference Standards | 1 | 2018 | 29 | 0.160 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 35 | 0.160 |
Why?
|
| Incidence | 3 | 2016 | 685 | 0.160 |
Why?
|
| Ethiopia | 1 | 2018 | 18 | 0.160 |
Why?
|
| Employment | 1 | 2018 | 27 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2018 | 7 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 198 | 0.150 |
Why?
|
| Prognosis | 2 | 2015 | 199 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 7 | 0.150 |
Why?
|
| Quality of Life | 1 | 2019 | 177 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 370 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 33 | 0.140 |
Why?
|
| Text Messaging | 1 | 2016 | 25 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2016 | 55 | 0.130 |
Why?
|
| Hospitals | 1 | 2016 | 103 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 127 | 0.130 |
Why?
|
| Developing Countries | 1 | 2018 | 400 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 37 | 0.120 |
Why?
|
| Counseling | 1 | 2016 | 143 | 0.120 |
Why?
|
| Survival Rate | 1 | 2015 | 96 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2015 | 133 | 0.120 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 278 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2014 | 4 | 0.120 |
Why?
|
| Benzoxazines | 1 | 2014 | 123 | 0.110 |
Why?
|
| Nevirapine | 1 | 2014 | 146 | 0.110 |
Why?
|
| Organophosphonates | 1 | 2013 | 45 | 0.110 |
Why?
|
| Lamivudine | 1 | 2013 | 89 | 0.110 |
Why?
|
| Adenine | 1 | 2013 | 91 | 0.100 |
Why?
|
| Pregnancy Outcome | 2 | 2025 | 117 | 0.100 |
Why?
|
| Pregnancy | 3 | 2025 | 1862 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2018 | 1160 | 0.080 |
Why?
|
| Tenofovir | 2 | 2025 | 171 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2018 | 21 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 253 | 0.070 |
Why?
|
| Child | 3 | 2019 | 2242 | 0.070 |
Why?
|
| Diketopiperazines | 1 | 2025 | 6 | 0.060 |
Why?
|
| Africa, Eastern | 1 | 2025 | 17 | 0.060 |
Why?
|
| Africa, Southern | 1 | 2025 | 91 | 0.060 |
Why?
|
| Emtricitabine | 1 | 2025 | 78 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 279 | 0.060 |
Why?
|
| Tennessee | 1 | 2023 | 1 | 0.060 |
Why?
|
| Students | 1 | 2023 | 50 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 73 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 101 | 0.050 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2025 | 196 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 1475 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 37 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2019 | 62 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 17 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2018 | 57 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 156 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 41 | 0.040 |
Why?
|
| Markov Chains | 1 | 2018 | 22 | 0.040 |
Why?
|
| Zambia | 1 | 2018 | 115 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2017 | 4 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2018 | 43 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 253 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 34 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2017 | 149 | 0.040 |
Why?
|
| Public Health | 1 | 2018 | 124 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 6 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 563 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 112 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 468 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 48 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 65 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 89 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 107 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2016 | 40 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 179 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 34 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 125 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 225 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 151 | 0.030 |
Why?
|
| Contraception | 1 | 2016 | 90 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 327 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 188 | 0.030 |
Why?
|
| Alkynes | 1 | 2014 | 117 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2014 | 123 | 0.030 |
Why?
|
| Viremia | 1 | 2014 | 66 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1422 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1192 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 321 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1748 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 2244 | 0.020 |
Why?
|
| HIV-1 | 1 | 2016 | 1260 | 0.020 |
Why?
|